Heart Failure Clinical Trial
Study to Evaluate Safety, Tolerability and Drug Levels of BMS-986435/MYK-224 in Participants With Heart Failure With Preserved Ejection Fraction (HFpEF)
Summary
The purpose of this study is to evaluate the safety, tolerability, and exposure-response (E-R) of BMS-986435/MYK-224 in participants with symptomatic Heart Failure with Preserved Ejection Fraction (HFpEF).
Eligibility Criteria
Inclusion Criteria
- Adult participants with stable, symptomatic HFpEF with a normal heart pumping ability.
Exclusion Criteria
Participants must not have a known diagnosis of obstructive or genetic hypertrophic cardiomyopathy or infiltrative/storage disorder such as cardiac amyloidosis, or any other acute or serious condition that could interfere with assessments during the study or may pose a risk to the participant.
Other protocol-defined Inclusion/Exclusion criteria apply.
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There are 34 Locations for this study
Birmingham Alabama, 35233, United States More Info
Contact
Miami Florida, 33133, United States More Info
Contact
Atlanta Georgia, 30322, United States More Info
Contact
Atlanta Georgia, 30322, United States
Indianapolis Indiana, 46260, United States
Saint Louis Missouri, 63136, United States
New York New York, 10065, United States More Info
Contact
Oklahoma City Oklahoma, 73135, United States
Houston Texas, 77025, United States
Toronto Ontario, M5S 1, Canada
Milano Lombardia, 20162, Italy
San Donato Milanese Lombardia, 20097, Italy
Foggia Puglia, 71100, Italy
Massa Toscana, 54100, Italy
Bialystok Podlaskie, 15-27, Poland
Krakow , 30-08, Poland
Lublin , 20-95, Poland
Oswiecim , 51162, Poland
Majadahonda Madrid, 28222, Spain
El Palmar Murcia, 30120, Spain
Malaga Málaga, 29010, Spain
Madrid , 28034, Spain
Sevilla , 41014, Spain
How clear is this clinincal trial information?